Premium
Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication
Author(s) -
Olweny Charles L. M.,
Toya Tom,
KatongoleMbidde Edward,
Mugerwa Josua,
Kyalwazi Sebastian K.,
Cohen Herman
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197510)36:4<1250::aid-cncr2820360410>3.0.co;2-x
Subject(s) - medicine , hepatocellular carcinoma , carcinoma , oncology
In a Phase II clinical trial, 14 patients with histologically proven primary hepatocellular carcinoma were treated with adriamycin administered intravenously at a dose of 75 mg/m 2 every 3 weeks. All 11 evaluable patients responded with 3 exhibiting complete tumor regression after two, three, and five courses of adriamycin respectively. The remission durations for these 3 were 3, 6, and 7 months, and their survivals were 8, 9, and 13 months, respectively. The median survival of the evaluable patients is 8 months (range 1–13 months). The side effects encountered included myelosuppression, anorexia, nausea, vomiting, and alopecia. Adriamycin seems to be an effective agent in hepatocellular carcinoma. Further trials are underway to test its true efficacy both singly and in combination with other drugs in the management of this tumor.